3 May 2017 - The FDA and PDA are co-sponsoring a conference to identify best practices for global development and approval for biosimilars.

The conference wil examine:

• Risk-based approaches to setting product specifications for quality attributes
  
• Practical solutions for establishing suitable control strategies over the biosimilar product lifecycle
  
• Approaches for global post-marketing change control
  
• Expectations for demonstrating analytical similarity
  

Read FDA blog